SIL declares profit from operations growth as +6% vs previous year
Mumbai: Sanofi India Limited has announced its financial results for the quarter ended June 30, 2025.
The Company recorded a 9% decline in net sales on a comparable basis of continuing business. In the Domestic market, the successful launch of Soliqua, its diabetes treatment for the premix segment, continues to gain momentum, reinforcing the company's comprehensive diabetes portfolio. Toujeo maintained strong performance with high single-digit growth.
The company's strategic partnerships in Cardiovascular (CV) and Central Nervous System (CNS) segments have established a solid foundation, meeting expectations for market reach expansion and business acceleration.
Export sales were affected by non-recurring CHC product sales from 2024 and the planned discontinuation of the Zentiva portfolio.
For the year-to-date period ended June 2025, the Company achieved a 6% increase in operating profit.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.